Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Inventory (2016 - 2026)

Bio-Techne has reported Inventory over the past 16 years, most recently at $205.4 million for Q4 2025.

  • For Q4 2025, Inventory rose 9.06% year-over-year to $205.4 million; the TTM value through Dec 2025 reached $205.4 million, up 9.06%, while the annual FY2025 figure was $189.4 million, 5.41% up from the prior year.
  • Inventory for Q4 2025 was $205.4 million at Bio-Techne, up from $203.2 million in the prior quarter.
  • Over five years, Inventory peaked at $205.4 million in Q4 2025 and troughed at $110.0 million in Q1 2021.
  • A 5-year average of $163.8 million and a median of $175.6 million in 2023 define the central range for Inventory.
  • Biggest five-year swings in Inventory: surged 32.1% in 2023 and later dropped 0.56% in 2024.
  • Year by year, Inventory stood at $121.9 million in 2021, then soared by 31.49% to $160.2 million in 2022, then grew by 12.86% to $180.8 million in 2023, then increased by 4.17% to $188.4 million in 2024, then increased by 9.06% to $205.4 million in 2025.
  • Business Quant data shows Inventory for TECH at $205.4 million in Q4 2025, $203.2 million in Q3 2025, and $189.4 million in Q2 2025.